Metastatic Hormone Refractory Prostate Cancer – Pipeline Review, H2 2012

Date: November 28, 2012
Pages: 104
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ME7419C0A6FEN
Leaflet:

Download PDF Leaflet

Metastatic Hormone Refractory Prostate Cancer – Pipeline Review, H2 2012
Metastatic Hormone Refractory Prostate Cancer – Pipeline Review, H2 2012

SUMMARY

Global Markets Direct’s, 'Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory Prostate Cancer. Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • A snapshot of the global therapeutic scenario for Metastatic Hormone Refractory Prostate Cancer.
  • A review of the Metastatic Hormone Refractory Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Hormone Refractory Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
REASONS TO BUY
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory Prostate Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Metastatic Hormone Refractory Prostate Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Hormone Refractory Prostate Cancer
Metastatic Hormone Refractory Prostate Cancer Therapeutics under Development by Companies
Metastatic Hormone Refractory Prostate Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Products under Development by Companies
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Hormone Refractory Prostate Cancer Therapeutics Development
Bristol-Myers Squibb Company
AstraZeneca PLC
Genentech, Inc.
Bavarian Nordic A/S
Millennium Pharmaceuticals, Inc.
Astellas Pharma Inc.
Teva Pharmaceutical Industries Limited
Active Biotech AB
Medivation, Inc.
Cadila Pharmaceuticals Ltd.
Ascenta Therapeutics, Inc.
Bellicum Pharmaceuticals, Inc.
Metastatic Hormone Refractory Prostate Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
orteronel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
custirsen sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tasquinimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
enzalutamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prostvac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD2171 + Docetaxel + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BPX-101 + AP1903 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zibotentan + Taxotere - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dasatinib + Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycobacterium w + Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ixabepilone + Mitoxantrone Hydrochloride + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ixabepilone + Mitoxantrone Hydrochloride + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
177Lu Radiolabeled Monoclonal Antibody HuJ591 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZD-4054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZD-4054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CreaVax-PC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Prednisone + 177Lu-J591 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mitoxantrone + Prednisone + Clodronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY43-9006 + Taxotere - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mitoxantrone + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-700 + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-101 + Prednisone + Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BPX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prostvac + GM-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-9521 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-7450 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Drug Profile Updates
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Discontinued Products
Metastatic Hormone Refractory Prostate Cancer Therapeutics - Dormant Products
Metastatic Hormone Refractory Prostate Cancer – Product Development Milestones
Featured News & Press Releases
Oct 03, 2012: Ipsen And Active Biotech Announce Initiation Of Phase II Trial In Metastatic Castrate-resistant Prostate Cancer With Tasquinimod
May 21, 2012: Dendreon To Present PROVENGE Data At American Urological Association Annual Meeting
Feb 03, 2012: Aeterna Zentaris Reports Updated Phase I Trial Results For AEZS-108 In Prostate Cancer At ASCO GCS Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Metastatic Hormone Refractory Prostate Cancer, H2 2012
Products under Development for Metastatic Hormone Refractory Prostate Cancer – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Bristol-Myers Squibb Company, H2 2012
AstraZeneca PLC, H2 2012
Genentech, Inc., H2 2012
Bavarian Nordic A/S, H2 2012
Millennium Pharmaceuticals, Inc., H2 2012
Astellas Pharma Inc., H2 2012
Teva Pharmaceutical Industries Limited, H2 2012
Active Biotech AB, H2 2012
Medivation, Inc., H2 2012
Cadila Pharmaceuticals Ltd., H2 2012
Ascenta Therapeutics, Inc., H2 2012
Bellicum Pharmaceuticals, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Drug Profile Updates
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Discontinued Products
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Dormant Products
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Dormant Products (Contd..1)

LIST OF FIGURES

Number of Products under Development for Metastatic Hormone Refractory Prostate Cancer, H2 2012
Products under Development for Metastatic Hormone Refractory Prostate Cancer – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012

Ask Your Question

Metastatic Hormone Refractory Prostate Cancer – Pipeline Review, H2 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: